Phytoterapy combined with prostate chronic inflammatory diseases and their complications in persons with diabetes mellitus


  • І. І. Горпинченко ГУ «Институт урологии НАМН Украины», г. Киев
  • Ю. М. Гурженко ГУ «Институт урологии НАМН Украины», г. Киев
  • В. В. Спиридоненко ГУ «Институт урологии НАМН Украины»



chronic prostatitis, diabetes, herbal medicine


The combination in patients with diabetes and chronic prostatitis, demonstrated lower urinary tract symptoms is urgent health and social issue and requires adequate diagnostic measures and medication adjustment. The aim of the study: to determine the long-term application of a combination of phytotherapy in men with lower urinary tract symptoms chronic prostatitis (CP) and diabetes mellitus (DM). Materials and methods. In the -Institute of urology of NAMS of Ukrainewere examined 63 patients with CP on the background of diabetes of 1-St and 2-nd type (mean age of 42.3±0.9 years). In the 1st group patients (n=30) were administered Pravenor 2 capsules per day after meals for 4 months with three 10-day intervals; in the 2nd group (n=33) patients taking the extract of pumpkin seeds ordinary 500 mg 2 times a day for 4 months. Control group (n=32) included almost healthy patients who did not receive treatment during the investigation period. The history of the disease CP amounted to an average of 5.2±0.8 years, SD of 12.8±0.9 years, the ratio of DM 1st / DM 2nd type 70:30%. Results. The use of drugs Pravenor® capsules and suppositories Pravenor was based on long-term medical effects on the inflammatory factor in the tissues of the pancreas. At the control examination one of the most significant indicators was the compensation of carbohydrate metabolism. During the inspection of patients of the 1st group in the control time (30 day) it was found that the use of herbal remedies Pravenor® capsules and suppositories Pravenor® provides a good clinical effect, improve the health and quality of life. Patients 1st clinical group receiving continuous combined therapy and improved almost all the indicators in comparison with the 2nd group. Thus, the maximum flow rate Vmax in patients of the 1st group improved by 24.8%, of urination for IPSS – by 20.6%, QoL – 46.5%, respectively (p<0.05). Patients of the 2nd group of such dynamics have been identified. Conclusion. The use of medicinal herbal remedies Pravenor® capsules and Pravenor suppositories in patients with CP with concomitant DM is a reasonable treatment strategy, contributing to the reduction of dysuric phenomena. The obtained results allow to recommend the use of Pravenor® capsules and suppositories Pravenor for the integrated treatment of patients with chronic pancreatitis on the background of diabetes.

Author Biographies

І. І. Горпинченко, ГУ «Институт урологии НАМН Украины», г. Киев

Горпинченко Игорь Иванович

Ю. М. Гурженко, ГУ «Институт урологии НАМН Украины», г. Киев

Гурженко Юрий Николаевич

Национальная медицинская академия последипломного образования имени П.Л. Шупика, г. Киев,

ГУ «Институт урологии» НАМН Украины, г. Киев

В. В. Спиридоненко, ГУ «Институт урологии НАМН Украины»

Спиридоненко Владимир Владимирович


Marchal de Calvi Ch.-J. Recherches sur les accidents diabétiques et essai d’une théorie générale de diabète. Asselin und Labé. 1864. – 658 p.

Ellenberg M., Weber H. Bladder decompensation correlates with diabetic neuropathy. JAMA. 1966; 197(7): 39.

Ellenberg M., Weber H. The incipient asymptomatic diabetic bladder. Diabetes 1967; 16(5): 331–335.

Dedov I.I., Kurbatov D.G. i soavt. Urologicheskie i andrologicheskie zabolevanija pri saharnom diabete // Urologija. – 2009. – № 4. – S. 74–79.

Kuz'min I.V., Shabudina N.O. Jepidemiologija i faktory riska razvitija narushenij mocheispuskanija u bol'nyh saharnym diabetom // Urologija, 2014. – № 6. – S. 114–118.

Hampel C. Gillitzer R., Pahernik S. et al. Diabetes mellitus and bladder function. What should be considered? Urol. 2003; 42 (12): P. 1556–1563.

Brown J.S. Diabetic cystopathy – what does it mean? Urol. 2009; 181(1): P. 13–14.

Ficarra V, Rossanese M, Zazzara M et. al. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy //Curr Urol Rep. 2014. Dec;15(12): P. 463.

Naber K., Weidner W. Chronic prostatitis: an infectious disease? // J Antimicrob. Chemother. – 2000. – V. 46. – P. 157–161.

De Marzo A.M. Pathological and molecular mechanisms of prostate cancerogenesis: implications for diagnosis, prevention and treatment // J Cell Biochem. – 2004. –V. 91. – P. 459–477.

Karakiewicz P.I., Benayoun S., Begin L.R. et al. Chronic inflammation is negatively associated with prostate cancer and high grade prostatic intraepithelial neoplasia on needle biopsy // Int J Clin Pract. – 2007. – V. 71. – P. 425–430.

Kramer G., Mitteregger D., Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? // Eur Urol. – 2007. – V. 51. – P. 1202–1216.

Elkahwaji J.E., Zhong W., Bushman W. Chronic bacterial infection and inflammation incite reactive hyperplasia in a mouse model of chronic prostatitis // Prostate. – 2007. – V. 67. – P. 14–21.

Ueda T., Yoshimura N., Yoshida O. Diabetic cystopathy: relationship to autonomic neuropathy detected by sympathetic skin response. J Urol. (Baltimore). 1997; 157(2): 580–584.

Yu H.J., Lee W.C., Liu S.P. et al. Unrecognized voiding difficulty in female type 2 diabetic patients in the diabetes clinic: a prospective case-control study. Diabetes Care. 2004; 27: 988–989.

Frimodt-Moller C. Diabetic cystopathy. I: A clinical study of the frequency of bladder dysfunction in diabetics. Dan. Med. Bull. 1976; 23: 267–278.

Liao Y., Li C., Chang L. et al. The time since the diagnosis of diabetes might be linked to lower urinary tract symptoms. Neurourol Urodyn. 2013; 32 (6): 700–701.

Sasaki K., Yoshimura N., Chancellor M.B. Implications of diabetes mellitus in urology. Urol. Clin. North. Am. 2003; 30: 1–12.

Frimodt-Moller C. Diabetic cystopathy: epidemiology and related disorders. Ann. Intern. Med. 1980; 92: 318–321.

Kolesnikova L.I., Darenskaya M.A., Grebenkina L.A. et al. Lipid peroxidation and protection in patients with diabetes mellitus type i during reproductive system development. Journal of Diabetes & Metabolism. 2013;4 (6):37.

Nelson W.G., De Marzo A.M., Isaacs W.B. Prostate cancer //N. Engl. J. Med. – 2003. – V. 349. – P. 366–381.

Tomas D., Krušlin B., Rogatsch H., et al. Different types of atrophy in the prostate with and without adenocarcinoma // Eur. Urol. – 2007. – V. 51. – P. 98–104.

Naber K., Weidner W. Chronic prostatitis: an infectious disease? // J Antimicrob. Chemother. – 2000. –V. 46. – P. 157–161.

De Marzo A.M., Platz E.A., Sutcliffe S. et al. Inflammation in prostate carcinogenesis // Nat Rev. – 2007. – V. 7. – P. 256–269.

Ko E.Y., Sabanegh E.S.Jr., Agarwal A. Male infertility testing: reactive oxygen species and antioxidant capacity. Fertil. Steril. 2014; 102:1518–1527.

Joffe M. What has happened to human fertility. Hum. Reproduction. 2010; 25:295–307.

Kolesnikova L.I., Kurashova N.A., Dolgih M.I. i soavt. Primenenie integral'nogo pokazatelja dlja ocenki okislitel'nogo stressa u muzhchin s patospermiej i saharnym diabetom 1-go tipa // Urologija. – 2015. – № 4. – S. 71–74.

Zagarskih E.Ju., Labygina A.V., Kurashova N.A. Opyt lechenija normogonadotropnogo besplodija. Urologija. 2014;5:87–89.

Gorpinchenko I.I., Romanjuk M.G., Aksenov P.V., Kornienko A.M. Svechi Pravenor – novoe slovo v fitoprofilaktike zabolevanij predstatel'noj zhelezy // Zdorov'e muzhchiny, 2015. – № 3 (54). – S. 65–70.

Gorpinchenko I.I. Gurzhenko Ju.M., Spiridonenko V.V. Teoretichne obg'runtuvannja efektivnosti fitoterapii' u cholovikiv iz zapal'nimi zahvorjuvannjami peredmihurovoi' zalozi // Zdorov'e muzhchiny, 2015. – № 4 (55). – S. 45–49.

Chua T., Eise N.T, Simpson J.S., Ventura S. Pharmacological characterization and chemical fractionation of a liposterolic extract of saw palmetto (Serenoa repens): effects on rat prostate contractility // J Ethnopharmacol. 2014 Mar 14; V. 152 (2): P. 283–91.

Forray C., Bard J.A., Wetzel J.M. et al. The b1adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human b1s subtype. Mol. Pharmacol. 1994; 45 (4): 703–708.

Goldstraw M.A., Fitzpatrick J.M., Kirby R.S. What is the role of inflammation in the pathogenesis of prostate cancer // BJU Int. – 2007. – V. 15. – P. 1–2.

Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome // Nature. – 2006. – V. 440. – P. 237–241.

Di Silverio F, Gentile V., De Matteis A. et al. Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis // Eur Urol. – 2003. – V. 43. – P. 164–175.

Bostanci Y., Kazzazi A., Momtahen S., Laze J., Djavan V. Correlation between benign prostatic hyperplasia and inflammation // BENIGN PROSTATIC HYPERPLASIA. 2013 – Vol. 23 (1). – R. 5–10.

Di Silverio F., Bosman C., Salvatori M. et al. Combination therapy with rofecoxib and finasteride in the treatment of men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) // Eur. Urol. – 2005. – V. 47 – P. 72–79.

De Marzo A.M. Pathological and molecular mechanisms of prostate cancerogenesis: implications for diagnosis, prevention and treatment // J Cell Biochem. – 2004. – V. 91. – P. 459–477.

Wu YN, Liao CH, Chen KC, Liu SP, Chiang HS. Effect of Ginkgo biloba Extract (EGb-761) on Recovery of Erectile Dysfunction in Bilateral Cavernous Nerve Injury Rat Model. Urology. 2015 May; 85 (5): 1214.7–15.

Urtica.Therapeutic and nutritional aspects of stinging nettles”. Edited by Gulsel M. Kavalali. Series: “Medicinal and Aromatic Plants – Industrial Profiles. 2003.

Dreikorn K., Richter R. Conservative nonhormonal treatment of patients with benign prostatic hyperplasia, in Ackerman R., and Schroeder F.H. (Eds): New Developments in Biosciences 5, Prostatic Hyperplasia. Brlin, New York, Walter de Gruyter &CO., 1989, pp. 109–131.

Marwick C. Growing use of medicinal botanicals forces assessment by drug regulators. JAMA 1995; 273: 607–9.

Dreikorn K., Borkowski A., Braeckman J., et al. Other Medical Therapies. Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia (BPH). Paris, Scientific Communication International Limited, 1997.

Lowe F.C., Ku J.C. Phytotherapy in treatment of benign prostatic hyperplasia: A critical review // Urology, 1996; 48:12.

Ahmed H.H., Fayez M., Diab A., El-Badry A.A. Effect of beta-sitosterol alone and in combination with naloxone or L-dopa on serum prolactin, luteinizing hormone and follicle stimulating hormone of female ovariectomised rate // J. Egypt Vet. Med. Ass. 1987; 47: 453–60.

Safarinejad M.R. Urtica dioica for treatment of benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled, crossover study // J Herb Pharmacother. 2005;5(4):1–11.

Zeng H., Wu M., Botnen J.H. Methylselenol, a selenium metabolite, induces cell cycle arrest in G1 phase and apoptosis via the extracellular-regulated kinase 1/2 pathway and other cancer signaling genes F //Journal of Nutrition, 2009, 139 (9), 1613–1618.

Zeng H., Briske-Anderson M., Wu M., Moyer M.R. Methylselenol, a selenium metabolite, plays common and different roles in cancerous colon HCT116 cell and noncancerous NCM460 colon cell proliferation // Nutrition and Cancer, 2012. 64, 128–135.

Chopik V.I., Dudchenko L.G, Krasnova A.N. Dikorastushhie poleznye rastenija Ukrainy. Spravochnik. – K.: Naukova dumka, 1983. – 400 s.

Rastitel'nye resursy SSSR. Cvetkovye rastenija, ih himicheskij sostav, ispol'zovanie. Semejstva Hedrangeaceae – Haloragaceae. – L., 1987.

Pepenin V.R., Spiridonenko V.V., Pepenin S.V. Vozmozhnosti jekstrakta jakorcev cteljushhihsja v terapii hronicheskogo prostatita i ego oslozhnenij // Zdorov'e muzhchiny. – 2009. – № 3. – S. 57–59.

Gorpinchenko I.I., Imshineckaja L.P., Gurzhenko Ju.N. Issledovanie jeffektivnosti preparata Tribestan dlja negormonal'nogo lechenija vtorichnogo gipogonadizma u muzhchin // Zdorov'e muzhchiny, 2011. – №3 (38). – S. 1–3.

Chhatre S., Nesari T., Somani G. et al. Phytopharmacological overview of Tribulus terrestris //Pharmacogn Rev. 2014 Jan-Jun; 8(15): 45–51.



For practicing physicians